Psilocybin-Research.com Searchable psychedelic science.
Loading
Psilocybin-Research.com Searchable psychedelic science.

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

Research workflow

Search, filter, export, analyze, and monitor psilocybin and psilocin publications with source labels, publication status, citation links, alerts, API access, and full SQLite download.

Databases used

  • PubMed
  • Crossref
  • Europe PMC
  • OpenAlex
  • medRxiv
  • bioRxiv
  • PsyArXiv
  • ClinicalTrials.gov

Psilocybin and psilocin research index

Find psilocybin and psilocin papers, preprints, trials, and citations.

Search settings and shortcuts
Database up to date Updated Jul 3, 2026 01:22 UTC
Database 3,975 indexed records
Current display Latest publications Full SQLite index sorted by newest first. Use search or filters to narrow the list.
Database 3,975 indexed records
3,975 Total Publications 3,834 Psilocybin Records 553 Psilocin Records 3,975 Search Matches 388 Journals 66 Research Topics
Published 3,210 Peer-reviewed / formal records
Preprints 478 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage 8 active sources
Source Count Share Status
Europe PMC 2,554 64.3% Active
PubMed 302 7.6% Active
ClinicalTrials.gov 287 7.2% Active
OpenAlex 283 7.1% Active
PsyArXiv 216 5.4% Active
Crossref 157 3.9% Active
bioRxiv 142 3.6% Active
Publication timeline 3,072 dated records
3,072 records since 2020
Annual records Cumulative line
Default publication index

Latest publications

3,975 records from the full SQLite publication database, sorted by newest first.

Result settings and export data
Updated Jul 3, 2026 01:22 UTC
Checking for newly indexed publications...
Page 29 of 199

Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.

ImportancePsychedelic-assisted therapy (PAT) is a novel intervention for depressive symptoms, typically delivered with additional psychological therapy sessions. Quantitative evidence on how this concomitant therapy contributes to treatment outcomes is limited, highlighting the need for a systematic synthesis.ObjectiveTo evaluate whether the quantity of psyc...

Unknown journal 2026-01-01 Florineth GA, Klima I, Boeker AL, Catzeflis P, Wopfner A, Denier N, Bracht T, Adorjan K, Pfammatter M, Müller F, Soravia LM.
Europe PMC Published psilocybin DepressionMicrodosingClinical TrialMeta-AnalysisSystematic ReviewReview ArticleCase ReportSafety Meta-Analysis HumansLysergic Acid Diethylamide

Snapshot IP1 Detection Following 5-HT2A Receptor Stimulation in the Mouse Brain.

The distinct subjective effects that define psychedelics such as lysergic acid diethylamide (LSD), psilocybin, or 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) as drug class are causally linked to the activation of the serotonin 2A receptor (5-HT2AR). However, some aspects of 5-HT2AR pharmacology remain elusive, such as what molecular drivers different...

Unknown journal 2026-01-01 de la Fuente Revenga M, González-Maeso J.
Europe PMC Published psilocybin End-of-Life DistressNeuroplasticityPharmacologyMechanism of ActionReceptor PharmacologyAnimal Study Animal Study BrainAnimals

Psilocibina en cuidados paliativos: revisión sistemática de los efectos a nivel emocional y espiritual-existenciales

Anxiety, depression, and existential distress are common symptoms in palliative care and significantly impair patients’ quality of life. Psilocybin-assisted therapy, based on preparation, therapeutic support, and psychotherapeutic integration, has emerged as a promising intervention to alleviate this complex cluster of suffering. The aim of this systematic r...

Revista Metropolitana de Ciencias Aplicadas 2025-12-31 Toalombo-Eugenio Graciela Estefanía, Carrillo-Zavala Katheryne Viviana, Mayorga-Núñez Verónica Giovanna
Crossref Published psilocybin DepressionAnxietyEnd-of-Life DistressHeadache / MigraineWellbeingEmotional ProcessingSpiritualityMystical ExperienceSystematic ReviewReview ArticleObservational StudySafetyAdverse Events Systematic Review

Psilocybin: clinical potential, mechanistic insights, and biotechnological advances for scalable production

Psilocybin, a tryptamine-derived alkaloid from Psilocybe mushrooms, has emerged as a high-value biopharmaceutical candidate due to its promising applications in mental health. While clinical studies highlight its rapid and sustained antidepressant effects, current challenges lie in achieving scalable, reproducible, and cost-effective production to meet growi...

Unknown journal 2025-12-31 Islas-Vargas J, Armenta S, Rivera-Román ÁA, Hernández-León S, Méndez-Hernández JE, Arce-Cervantes O.
Europe PMC Published psilocybin General Other

Toxicology and Pharmacological Interactions of Classic Psychedelics.

As psychedelics are being investigated for more medical indications, it has become important to characterize the adverse effects and pharmacological interactions with these medications. This chapter will summarize what is known about the toxicology and drug-drug interactions for classic psychedelics, such as LSD, psilocybin, DMT, 5-MeO-DMT, mescaline, 2C-B, ...

Unknown journal 2025-12-31 Thomas K.
Europe PMC Published psilocybin ToxicityDrug Interactions Other AnimalsHumans

Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms.

Psychedelics are a group of substances within the heterogeneous class of hallucinogenic drugs. Via binding to the serotonin (5-HT) 2A receptor, psychedelics exert profound alterations in various mental domains, including sensation, cognition, emotions, and self-perception. Psychedelics comprise phenethylamines (e.g., mescaline), tryptamines (e.g., psilocybin...

Unknown journal 2025-12-31 Holze F, Liechti ME, Müller F.
Europe PMC Published psilocybin AnxietyPharmacologyReceptor PharmacologyEmotional ProcessingSafetyAdverse EventsDrug Interactions Other AnimalsHumans

Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.

There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety disorders, but very few studies have examined the inverse of this, that is, the potential for psychedelics to inflict anxiety and affective symptoms. A systematic literature search was performed and 39 papers were inc...

Current topics in behavioral neurosciences 2025-12-31 Viljoen G, Betzler F
PubMed Published psilocybin DepressionAnxietyEmotional ProcessingSystematic ReviewReview ArticleSafety Systematic Review Affective disordersAnxiety

Informed Consent in Psychedelic-Assisted Therapy.

Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymethamphetamine (MDMA), emerged during the twentieth century and have likewise seen use in a broad range of settings. Interest has arisen in the use of classical psychedelics and entactogens, together termed "psychedeli...

Unknown journal 2025-12-31 Bradberry MM, Appelbaum PS, Gukasyan N.
Europe PMC Published psilocybin Safety Other HumansHallucinogens

Development of Psilocybe Mushroom Species Reference Material-Cultivation Parameters and Chemical Profiles.

BackgroundPsilocybin-containing mushrooms are gaining the attention of the scientific community due to the potential benefits offered by their psychoactive phytochemicals in the treatment of addiction and various mental health conditions. Although there are hundreds of different Psilocybe species, only a handful have been successfully cultivated under indoor...

Unknown journal 2025-12-31 Windsor C, Kreynes AE, Chilton JS, Chioffi WA, Niebergall C, Dodds K.
Europe PMC Published psilocybinpsilocin Addiction Other AgaricalesMycelium

Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi.

BackgroundThe consumption of dried fruiting bodies of Psilocybe cubensis can be traced over centuries, guided by Mesoamerican curanderas, Western medical practitioners, and fungal enthusiasts, all seeking mental wellbeing. There is a notable resurgence in interest both in the fungal biomass and psilocybin, the psychoactive tryptamine, despite the global regu...

Unknown journal 2025-12-31 Foster K, Morrison I, Daniel S, Antoine J, Thankappan B, De La Haye W, Tyler M, Grant C, Delgoda R.
Europe PMC Published psilocybinpsilocin WellbeingClinical TrialHealthcare Workers Clinical Trial FungiMetals

Building standards of psychedelic care: Qualitative examination of expert perspectives on safety, inclusion, and accountability.

There remain significant gaps in knowledge about best practices for facilitated psychedelic care and psychedelic-assisted therapy. To inform the development of service models that support safe and beneficial experiences, this qualitative study explored expert perspectives on current and ideal standards of care, including key practices (e.g., screening, adapt...

The International journal on drug policy 2025-12-31 Chwyl C, Wilson-Poe AR, Hoffman KA, Bazinet A, Pertl K, Luoma JB, des Jarlais D, Bielavitz S, Korthuis PT
PubMed Published psilocybin AddictionSafety Qualitative Study Harm reductionPsilocybin

Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics.

Classic psychedelics such as LSD, psilocybin, and DMT from unregulated markets pose considerable risks through unknown adulterants and potencies. In this chapter, we explore the importance of drug checking in minimizing harm among users of classic psychedelics and examine the opportunities and challenges associated with intervention settings, analytical tech...

Unknown journal 2025-12-31 Hirschfeld T, Blei F, Stegemann L, van der Gouwe D, Smit-Rigter L.
Europe PMC Published psilocybin Safety Other HumansLysergic Acid Diethylamide

Psilocybin Outside the Clinic: Public Health Challenges of Increasing Publicity, Accessibility, and Use.

ImportancePsilocybin use has surged in the US following decriminalization efforts and promising clinical trial results. Mirroring early cannabis legalization, public access and enthusiasm are outpacing regulatory oversight and scientific understanding, posing potential risks to public health.ObjectiveTo review emerging evidence on the public health implicati...

Unknown journal 2025-12-31 Hutchison KE, Hooper JF, Karoly HC.
Europe PMC Published psilocybin Clinical TrialReview ArticleSafetyAdverse Events Clinical Trial HumansHallucinogens

Live source coverage

3,975 indexed records across 8 active sources.

3,210Published
478Preprints
287Clinical trials
  1. Europe PMC 2,554 records · 64.3%
  2. PubMed 302 records · 7.6%
  3. ClinicalTrials.gov 287 records · 7.2%
  4. OpenAlex 283 records · 7.1%
  5. PsyArXiv 216 records · 5.4%
  6. Crossref 157 records · 3.9%
  7. bioRxiv 142 records · 3.6%
  8. medRxiv 34 records · 0.9%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.